Everything below concerns Visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-22. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Intensive airstrikes continued across Suwayda following the announcement of a ceasefire. The airstrikes targeted military equipment and convoys. One Syrian army convoy was struck in Suwayda, resulting in at least one casualty. The Mar Mikhael Church in the town of as-Sawra al-Kabira was robbed, vandalized, and burned. The group Men of Dignity announced over 50 of their members killed or injured in Suwayda clashes. On 16 July 2025, Sheikh Hikmat al-Hijri issued a statement, in which he appealed to Donald Trump, Benjamin Netanyahu, Mohammed bin Salman and Abdullah II to save Suwayda, stating that "the mask has fallen off the face of the ruling clique" and declaring, "we can no longer live with a regime that knows nothing of governance except iron and fire". Israel conducted airstrikes on several government buildings in Damascus, including the Syrian military headquarters, Israel Katz declared that the era of mere warnings in Damascus has ended, stating that "painful blows" will now be delivered to the Syrian government. Katz emphasized that the IDF will persistently and forcefully act in Suwayda to dismantle the forces responsible for attacking the Druze community until they fully withdraw. Addressing the Druze community in Israel, he reassured them that they can rely on the Israel Defense Forces for protection of their brethren in Syria, affirming that both he and Prime Minister Netanyahu have made a firm commitment to uphold this promise, The Syrian Ministry of Health reported three killed and 34 injured as a result of the attacks.
Theranos Inc. () was an American privately held corporation that was touted as a breakthrough health technology company. Founded in 2003 by then–19-year-old Elizabeth Holmes, Theranos raised more than US$700 million from venture capitalists and private investors, resulting in a $9 billion valuation at its peak in 2013 and 2014. The company falsely claimed that it had devised blood tests that could be performed rapidly and accurately, while requiring very small amounts of blood, all using compact automated devices that the company had developed. A turning point came in 2015, when medical research professor John Ioannidis, and later, professor of clinical biochemistry Eleftherios Diamandis, along with investigative journalist John Carreyrou of The Wall Street Journal, questioned the validity of Theranos's technology. The company faced a string of legal and commercial challenges from medical authorities, investors, the U.S. Securities and Exchange Commission (SEC), the Centers for Medicare and Medicaid Services (CMS), state attorneys general, former business partners, patients, and others. By June 2016, Forbes estimated that Holmes' personal net worth had dropped from $4.5 billion to "nothing". After several years of struggle, lawsuits, and sanctions from CMS, what remained of the company was dissolved in September 2018. Theranos, Holmes, and former company president Sunny Balwani were charged with fraud by the SEC in 2018.
=== Off-label drugs === Anticonvulsants (e.g., valproic acid) Atypical antipsychotics (e.g., quetiapine) Azapirones (serotonin 5-HT1A receptor agonists) (e.g., buspirone) Benzodiazepines (GABAA receptor positive allosteric modulators) (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam) Beta blockers (e.g., propranolol) Gabapentinoids (α2δ subunit-containing voltage-gated calcium channel ligands) (e.g., gabapentin, pregabalin) Monoamine oxidase inhibitors (MAOIs) (e.g., isocarboxazid, moclobemide, phenelzine, tranylcypromine) NMDA receptor antagonists (e.g., ketamine, esketamine) Selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, fluvoxamine) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., desvenlafaxine, duloxetine, levomilnacipran, milnacipran) Serotonin modulators and stimulators (SMSs) (e.g., vilazodone, vortioxetine) Tricyclic antidepressants (TCAs) (e.g., amitriptyline, clomipramine, doxepin, imipramine) Tetracyclic antidepressants (TeCAs) (e.g., mirtazapine) Others (e.g., hydroxyzine)
The core macrocycle, prerapamycin (figure 2), is then modified (figure 3) by an additional five enzymes, which lead to the final product, rapamycin. First, the core macrocycle is modified by RapI, SAM-dependent O-methyltransferase (MTase), which O-methylates at C39. Next, a carbonyl is installed at C9 by RapJ, a cytochrome P-450 monooxygenases (P-450). Then, RapM, another MTase, O-methylates at C16. Finally, RapN, another P-450, installs a hydroxyl at C27 immediately followed by O-methylation by Rap Q, a distinct MTase, at C27 to yield rapamycin. The biosynthetic genes responsible for rapamycin synthesis have been identified. As expected, three extremely large open reading frames (ORF's) designated as rapA, rapB, and rapC encode for three extremely large and complex multienzymes, RapA, RapB, and RapC, respectively. The gene rapL has been established to code for a NAD+-dependent lysine cycloamidase, which converts L-lysine to L-pipecolic acid (figure 4) for incorporation at the end of the polyketide. The gene rapP, which is embedded between the PKS genes and translationally coupled to rapC, encodes for an additional enzyme, an NPRS responsible for incorporating L-pipecolic acid, chain termination and cyclization of prerapamycin. In addition, genes rapI, rapJ, rapM, rapN, rapO, and rapQ have been identified as coding for tailoring enzymes that modify the macrocyclic core to give rapamycin (figure 3).
Sources: en.wikipedia.org
Earthworms are preyed upon by many species of birds (e.g. robins, starlings, thrushes, gulls, crows), snakes, wood turtles, mammals (e.g. bears, boars, foxes, hedgehogs, pigs, moles) and invertebrates (e.g. ants, flatworms, ground beetles, centipedes, snails, and spiders). Earthworms have many internal parasites, including fungi, protozoa, platyhelminthes, mites, and nematodes; they can be found in the worms' blood, seminal vesicles, coelom, intestine, or in their cocoons.) The earthworm activity aerates and mixes the soil (bioturbation), and is conducive to mineralization of nutrients and their uptake by vegetation together with incorporating organic matter and linking it to soil minerals. Certain species of earthworm come to the surface and graze on the higher concentrations of organic matter present there, mixing it with the mineral soil (anecic earthworms). Because a high level of organic matter mixing is associated with soil fertility, an abundance of earthworms is generally considered beneficial by farmers and gardeners. As long ago as 1881 Charles Darwin wrote: "It may be doubted whether there are many other animals which have played so important a part in the history of the world, as have these lowly organized creatures." It has long been debated whether earthworms contribute to the disappearance of organic matter in the form of carbon dioxide and mineral nutrients or rather to its preservation in the form of humus.
It has also been posited that in the region beyond A > 300, an entire "continent of stability" consisting of a hypothetical phase of stable quark matter, comprising freely flowing up and down quarks rather than quarks bound into protons and neutrons, may exist. Such a form of matter is theorized to be a ground state of baryonic matter with a greater binding energy per baryon than nuclear matter, favoring the decay of nuclear matter beyond this mass threshold into quark matter. If this state of matter exists, it could possibly be synthesized in the same fusion reactions leading to normal superheavy nuclei, and would be stabilized against fission as a consequence of its stronger binding that is enough to overcome Coulomb repulsion.
During 1973–2013, Khavinson et al., extracted from various organs over 20 complexes of physiologically active peptides, as well as 15 others synthesized from amino acids, (di-, tri-, tetrapeptides), all being covered by patents in many countries including the US, Canada, Australia, Europe, Japan, Korea, Israel, etc. After many years of experimental and clinical studies, six medicinal peptide preparations were permitted for medical use in the USSR, Russia, and afterward in the CIS countries. They were primarily to be used by the military medical service. These are ‘Thymalin’- a preparation of the thymus, being a cellular immunity regulator; ‘Epithalamin’ — a preparation from the pineal gland — regulator of the endocrine system, which restores melatonin, (with no analogues worldwide) ‘Cortexin’ — a preparation from the cerebral cortex, brain function regulator; ‘Prostatilen’ or ‘Samprost’ or ‘Vitaprost’ — a preparation from the prostate gland, regulator of prostate function; ‘Retinalamin’ — a preparation from the retina, partially restores functions of the retina in case of laser lesions and degenerative diseases, has no analogues worldwide; ‘Thymogen’ — a dipeptide EW, being first extracted from ‘Thymalin’, then synthesized from amino acids, regulates immunity. These medicinal peptide preparations were first used to restore immune functions of the brain, endocrine system, retina, etc.
Photochemistry – study of chemical reactions that proceed with the absorption of light by atoms or molecules. Quantum chemistry – branch of chemistry whose primary focus is the application of quantum mechanics in physical models and experiments of chemical systems. Solid-state chemistry – study of the synthesis, structure, and properties of solid phase materials, particularly, but not necessarily exclusively of, non-molecular solids. Spectroscopy – study of the interaction between matter and radiated energy. Stereochemistry – study of the relative spatial arrangement of atoms that form the structure of molecules Surface science – study of physical and chemical phenomena that occur at the interface of two phases, including solid–liquid interfaces, solid–gas interfaces, solid–vacuum interfaces, and liquid-gas interfaces. Thermochemistry – the branch of chemistry that studies the relation between chemical action and the amount of heat absorbed or generated. Calorimetry – the study of heat changes in physical and chemical processes. Organic chemistry (outline) – study of the structure, properties, composition, mechanisms, and reactions of organic compounds. An organic compound is defined as any compound based on a carbon skeleton. Biochemistry – study of the chemicals, chemical reactions and chemical interactions that take place in living organisms. Biochemistry and organic chemistry are closely related, as in medicinal chemistry or neurochemistry. Biochemistry is also associated with molecular biology and genetics.
Another non-curative treatment for patients with ADA-SCID is enzyme replacement therapy, in which the patient is injected with polyethyleneglycol-coupled adenosine deaminase (PEG-ADA), which metabolizes the toxic substrates of the ADA enzyme and prevents their accumulation. Treatment with PEG-ADA may be used to restore T cell function in the short term, enough to clear any existing infections before proceeding with curative treatment such as a bone marrow transplant.
Sources: en.wikipedia.org
=== Pathological sweating and symptoms === Diaphoresis may be associated with some abnormal conditions, such as hyperthyroidism and shock. If it is accompanied by unexplained weight loss, fever/chills, or by palpitations, shortness of breath, unconsciousness, fatigue, dizziness, muscle pain, nausea, vomiting, diarrhea, and chest discomfort, it suggests serious illness. Diaphoresis is also seen in an acute myocardial infarction (heart attack), from the increased firing of the sympathetic nervous system, and is frequent in serotonin syndrome, which can result in serious sickness or even death. Diaphoresis can also be caused by many types of infections, often accompanied by high fever and/or chills which can trigger the result of hyperthermia. Most infections can cause some degree of diaphoresis and it is a very common symptom in some serious infections such as malaria and tuberculosis. In addition, pneumothorax can cause diaphoresis with splinting of the chest wall. Neuroleptic malignant syndrome and other malignant diseases (e.g. leukemias) can also cause diaphoresis. Diabetics relying on insulin shots or oral medications may have low blood sugar (hypoglycemia), which can also cause diaphoresis. Drugs (including caffeine, morphine, alcohol, antidepressants and certain antipsychotics) may be causes, as well as withdrawal from alcohol, benzodiazepines, nonbenzodiazepines or narcotic painkiller dependencies. Sympathetic nervous system stimulants such as cocaine and amphetamines have also been associated with diaphoresis.
The precipitation of albumin is done by reducing the pH to 4.8, near the pH of the proteins, and maintaining the ethanol concentration at 40%, with a protein concentration of 1%. Thus, only 1% of the original plasma remains in the fifth fraction. When the ultimate goal of plasma processing is a purified plasma component for injection or transfusion, the plasma component must be highly pure. The first practical large-scale method of blood plasma fractionation was developed by Edwin J. Cohn during World War II. it's known as the Cohn process (or Cohn method). This process is also known as cold ethanol fractionation, as it involves gradually increasing the concentration of ethanol in the solution at 5 °C and 3 °C. The Cohn Process exploits differences in plasma proteins properties, specifically, the high solubility and low pI of albumin. As the ethanol concentration is increased in stages from 0 to 40%, the pH declines from neutral (pH ~ 7) to about 4.8, which is near the pI of albumin. At each stage, proteins are precipitated out of the solution and removed. The final precipitate is purified albumin. Several variations to this process exist, including an adapted method by Nitschmann and Kistler that uses fewer steps, and replaces centrifugation and bulk freezing with filtration and diafiltration. Some newer methods of albumin purification add additional purification steps to the Cohn process and its variations. Chromatographic albumin processing emerged in the 1980s, however, it was not widely adopted until later due to the scarity of large-scale chromatography equipment.
== Function == Generally, S100A12 has a significant anti-infectious and antibacterial role that is related to its ability to uptake ions. For example, it inhibits the spread and virulence of H. pylori.
==== Potassium ==== High concentrations of potassium (K+) also causes the muscle cells to decrease in efficiency, causing cramping and fatigue. Potassium builds up in the t-tubule system and around the muscle fiber as a result of action potentials. The shift in K+ changes the membrane potential around the muscle fiber. The change in membrane potential causes a decrease in the release of calcium (Ca2+) from the sarcoplasmic reticulum.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.